Can a new model of care introduced in General Practice improve detection and management of Familial Hypercholesterolaemia?

Not Applicable

Completed

• Conditions: Familial Hypercholesterolaemia; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12616000630415
• Lead Sponsor: The University of Notre Dame Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-16
• Study Completion: 2020-10-13
• Last Update Posted: 5 July 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 133

Inclusion Criteria

All patients from five participating GP clinics in Perth Western Australia, four in New South Wales, three in Queensland, two in Tasmania and one in Victoria, currently seeing registered GP in the last two years on at least one occasion will have records screened. All active patients who have ever had a record of either total cholesterol >7.0mmol/l or LDL-c >4.0mmol/l, including those patients on medications to reduce cholesterol (statins) will then be contacted by the GP for further examination and potential treatment.

Exclusion Criteria

No diagnosis of Familial Hypercholesterolaemia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of clinically diagnosed index cases of FH identified through use of screening tool (TARB-Ex), subsequent GP review of medical records, and recall of patients for confirmed diagnosis using the Dutch Lipid Clinic Network Criteria.<br><br><br>[12 months post screening of patient records with TARB-Ex screening tool in general practice. ];Number of patients with FH that have reduced LDL-c. This data will be extracted from medical records of patients who are initially diagnosed with FH from the screening protocol and agree to be part of the study. Six and 12 month reviews will be requested to monitor blood cholesterol levels. [Six and 12 months after clinical diagnosis of FH]